Takeshi Fuchigami, Kohei Shimo, Toya Hiwatashi, Yuka Andoh, Masayuki Munekane, Kenji Mishiro, Hiroaki Echigo, Hiroshi Wakabayashi, Yoji Kitamura, Seigo Kinuya, et al. Development of a Radiogallium-Labeled Heterodivalent Imaging Probe Targeting Negative Charges and Integrin on the Surface of Cancer Cell Membranes. Molecular Pharmaceutics. 2025
Saki Hirata, Kenji Mishiro, Kohshin Washiyama, Masayuki Munekane, Takeshi Fuchigami, Yasushi Arano, Kazuhiro Takahashi, Seigo Kinuya, Kazuma Ogawa. In Vivo Stability Improvement of Astatobenzene Derivatives by Introducing Neighboring Substituents. Journal of Medicinal Chemistry. 2025
Takeshi Fuchigami, Mya Mya, Ngwe Tun, Yusuke Tanahara, Kodai Nishi, Sakura Yoshida, Kazuma Ogawa, Morio Nakayama, Daisuke Hayasaka. Development of 111In-Labeled Monoclonal Antibodies Targeting SFTSV Structural Proteins for Molecular Imaging of SFTS Infectious Diseases by SPECT. Molecules. 2024. 30. 38
Masayuki Munekane, Miki Ozaki, Yuri Mitani, Natsuki Sakaida, Kohei Sano, Toshihide Yamasaki, Takahiro Mukai, Kenji Mishiro, Takeshi Fuchigami, Kazuma Ogawa. Development of Radiolabeled Probes with Improved Imaging Contrast by Releasing Urinary Excretable Radiolabeled Compounds from Thermosensitive Liposomes in the Blood. Molecular pharmaceutics. 2024. 21. 11. 5728-5735
Ayako Tagawa, Takeshi Fuchigami, Yusuke Miyanari. Development of nanobodies against human Survivin, applicable to suppress cell proliferation. bioRxiv. 2024
Combination therapy of 211At-labeled RGD peptide with immune checkpoint blockade to enhance anti-tumor efficacy
(EANM 2024 Annual Congress of the European Association of Nuclear Medicine 2024)
Development of stable astatine labeling sites
(The 12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS2024) 2024)